ŚRODEK PRZECIWNOWOTWOROWY I SPOSÓB PRZEWIDYWANIA EFEKTU TERAPEUTYCZNEGO U PACJENTÓW Z RAKIEM JELITA GRUBEGO Z MUTACJĄ KRAS

• 收藏
• 分享

专利权人:

Taiho Pharmaceutical Co.; Ltd.

发明人:

ITO, MASANOBU,OKABE, HIROYUKI

申请号：

PL12824342

公开号：

PL2746404T3

申请日:

2012.08.15

申请国别(地区):

PL

年份:

2018

代理人:

摘要：

This invention provides a method for predicting a therapeutic effect of chemotherapy that uses an antitumor agent comprising ±,±,±-trifluorothymidine and 5-chloro-6-(1-(2-iminopyrrolidinyl)methyl)uracil hydrochloride at a molar ratio of 1:0.5 on a colorectal cancer patient, the method comprising: (1) detecting the presence or absence of KRAS gene mutation in a biological sample obtained from the patient； and (2) predicting that the patient is likely to sufficiently respond to the chemotherapy, when KRAS gene mutation is detected in Step (1).

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/